How Do Mounjaro and Wegovy Starter Doses Compare?
Mounjaro or Wegovy UK: Understanding Your Starter Dose Options
When comparing Mounjaro or Wegovy UK starter doses, the key difference lies in both the initial dosage and underlying mechanisms. Wegovy begins with 0.25mg weekly injections for the first four weeks, designed as a gentle introduction to semaglutide's GLP-1 effects on appetite regulation. This lower starting dose helps minimise potential gastrointestinal side effects whilst allowing your body to adjust gradually. Mounjaro starts at 2.5mg weekly, reflecting tirzepatide's dual-action formula that targets both GIP and GLP-1 receptors simultaneously.
The starter dose period serves as your foundation for long-term success with either medication. Wegovy's 0.25mg starter dose typically produces subtle appetite changes in the first month, with more noticeable effects emerging as you progress through the escalation schedule. Both medications require prescription-only access through clinical assessment, ensuring your chosen starter dose aligns with your medical history and weight management goals. Your prescriber will evaluate factors such as current BMI, existing health conditions, and previous weight loss attempts when recommending between these options.
Wegovy Starter Pricing and Bundle Options
Wegovy's starter dose at 0.25mg costs £79.99 through EverydayMeds, making it an accessible entry point for beginning your weight management journey. New customers can apply discount code FIRST40 at checkout to reach this price, whilst returning customers use DOSE25 for ongoing orders. The Intro Duo bundle combines your first two doses (0.25mg and 0.5mg) for £169.99, providing eight weeks of treatment in a single order. This bundle approach ensures continuity of supply without requiring multiple prescription renewals during your initial escalation period.
For those preferring to extend their starter dose period, the Consistency 0.25mg bundle offers two 0.25mg pens for £139.99, allowing eight weeks at the initial dose if recommended by your prescriber. The Intro Trio (0.25mg, 0.5mg, and 1mg) provides three months of progressive doses for £299.99, ideal for patients wanting Reliable Supply throughout their early treatment phase. All orders include next-day delivery with temperature-controlled packaging to maintain medication integrity from our GPhC-registered pharmacy (#9012878).
Clinical Evidence Comparing Mounjaro or Wegovy UK Effectiveness
Clinical trials demonstrate both medications' effectiveness when comparing Mounjaro or Wegovy UK outcomes, though direct head-to-head studies remain limited due to different trial designs and patient populations. Wegovy's STEP 1 trial showed participants achieved approximately 15% average weight loss at 68 weeks when combined with diet and exercise, starting from the 0.25mg dose and escalating to 2.4mg maintenance (Wilding et al., NEJM, 2021). The gradual dose escalation beginning with 0.25mg proved crucial for tolerability and long-term adherence.
Mounjaro's SURMOUNT-1 trial demonstrated significant weight reduction with tirzepatide's dual-receptor approach, though comparing exact percentages would be misleading given different study methodologies and endpoints. Both medications require combination with reduced-calorie diet and increased physical activity to achieve optimal results. The choice between starting doses should consider individual tolerance patterns, lifestyle factors, and prescriber recommendations rather than focusing solely on trial outcomes.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to regulate appetite and food intake. Starting with the 0.25mg dose allows gradual introduction of this mechanism, which works primarily in your brain's appetite centres to reduce hunger signals and promote satiety after smaller meals. The medication slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Many patients notice reduced food cravings and decreased interest in high-calorie foods as the medication takes effect. This mechanism differs from Mounjaro's dual GIP + GLP-1 approach, offering a single-pathway solution that many patients find effective for long-term weight management alongside lifestyle modifications.
Ordering Process: From Assessment to Delivery
Beginning your Mounjaro or Wegovy UK treatment starts with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review your information within 3 working days (or 24 hours with express service) to determine suitability for either starter dose option. Upon approval, your chosen medication ships via next-day delivery using cold-chain transport to maintain optimal temperature throughout transit. Each order includes detailed injection instructions, dose escalation schedules, and direct access to our clinical support team for ongoing questions. The entire process from assessment to delivery typically takes 4-5 days, ensuring you can begin treatment quickly whilst maintaining full clinical oversight and safety protocols.
Storage Requirements and Practical Considerations
Wegovy requires refrigeration at 2-8°C before first use, but offers a significant storage advantage with 6 weeks of room temperature stability below 30°C once removed from the fridge. This compares favourably to Mounjaro's 21-day room temperature limit, making Wegovy more convenient for travel or situations where refrigeration access may be limited. Each Wegovy pen uses Novo Nordisk's FlexTouch system for easy self-injection, with clear dosage markings and automatic safety features. The dose escalation schedule progresses every 4 weeks (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg maintenance), with each increase carefully timed to optimise tolerability whilst building therapeutic effect. Both medications require consistent weekly injection timing, but Wegovy's extended room temperature stability provides greater flexibility for maintaining your dosing schedule during busy periods.
Mounjaro or Wegovy UK: First-Time Patient Considerations
First-time patients comparing Mounjaro or Wegovy UK starter doses often benefit from understanding each medication's side effect profile during the initial weeks. Wegovy's 0.25mg starter dose typically produces mild nausea in approximately 20% of patients, usually subsiding as your body adjusts to the medication. Starting slowly with this lower dose allows gradual tolerance building, which many prescribers prefer for patients new to GLP-1 treatments. The four-week starter period provides adequate time to assess your individual response before progressing to higher doses.
Patient support during the starter phase includes access to our clinical team for side effect management, dietary guidance, and injection technique refinement. Many patients find the first month's appetite changes encouraging but subtle, with more pronounced effects emerging during the 0.5mg and 1mg doses. Documentation of your starter dose experience helps inform future dose adjustments and ensures optimal long-term outcomes. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to switch between options if your initial choice doesn't provide expected results.
Begin Your Treatment Today with Expert Support
Starting your weight management journey with either Mounjaro or Wegovy UK begins with selecting the right starter dose approach for your individual needs and preferences. EverydayMeds provides both options through our comprehensive clinical assessment process, ensuring you receive appropriate prescriber oversight and ongoing support throughout your treatment. New customers can use discount code FIRST40 at checkout, whilst returning customers apply DOSE25 to access our competitive pricing structure. Our next-day delivery service ensures rapid treatment initiation once your prescription is approved. Visit https://everydaymeds.co.uk/products/wegovy-0-25mg to begin your clinical assessment and take the first step toward sustainable weight management with professional medical support from our GPhC-registered pharmacy team.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
